DRI Healthcare Trust (TSE:DHT.UN) Sets New 1-Year High – Here’s Why

Shares of DRI Healthcare Trust (TSE:DHT.UN) reached a new 52-week high during mid-day trading on Monday. The stock traded as high as C$19.75 and last traded at C$19.67, with a volume of 24,523 shares. The stock had previously closed at C$19.23.

Analyst Ratings Changes

Several research firms recently commented on DHT.UN. Stifel Nicolaus increased their price objective on DRI Healthcare Trust from C$25.00 to C$26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. National Bank Financial lifted their target price on shares of DRI Healthcare Trust from C$23.50 to C$25.50 and gave the stock an “outperform” rating in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. Based on data from MarketBeat, DRI Healthcare Trust has a consensus rating of “Buy” and an average price target of C$25.60.

DRI Healthcare Trust Price Performance

The stock has a market capitalization of C$1.07 billion, a price-to-earnings ratio of 18.07 and a beta of 0.09. The business has a fifty day moving average of C$18.08 and a 200 day moving average of C$17.38.

DRI Healthcare Trust Company Profile

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.